MMV253

Zydus Cadila

Product vision
  • Part of a single-exposure radical cure

MoA
  • Unknown (resistance mutants identified in vacuolar ATP-synthase sub-unit D indicating possible biological target)

Key features
  • Predicted 280-520mg human dose gives concentrations above Minimal Parasiticidal Concentration for >6 days

  • Low resistance potential from in vitro studies

Challenges
  • Active metabolite; synthesis and cost of goods

Status
  • Approved as preclinical candidate in 2014

  • Licensed to Zydus in September 2016

  • Global Safety Board approved moving forward to First-in-Man study

Next milestone
  • Start of First-in-Man study in 2019

Previously
  • Name AZ13721412; from a discovery partnership with AstraZeneca, Bangalore

MMV Project Director
  • Dr Andrew Slade